PharMerica Co. (NYSE:PMC) CEO Gregory S. Weishar sold 521,089 shares of PharMerica stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $29.25, for a total transaction of $15,241,853.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of PharMerica Co. (NYSE PMC) traded up $0.05 during trading on Monday, reaching $29.25. 1,371,600 shares of the company’s stock were exchanged, compared to its average volume of 283,015. The company has a current ratio of 2.58, a quick ratio of 1.79 and a debt-to-equity ratio of 0.79. The stock has a market cap of $910.27, a P/E ratio of 15.15, a P/E/G ratio of 1.27 and a beta of 0.82. PharMerica Co. has a fifty-two week low of $22.00 and a fifty-two week high of $29.50.

PharMerica (NYSE:PMC) last issued its quarterly earnings data on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.49 by ($0.03). The company had revenue of $595.10 million for the quarter, compared to analysts’ expectations of $596.80 million. PharMerica had a net margin of 0.83% and a return on equity of 10.94%. sell-side analysts expect that PharMerica Co. will post 1.92 EPS for the current fiscal year.

A number of research analysts have issued reports on PMC shares. Zacks Investment Research downgraded shares of PharMerica from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. ValuEngine raised shares of PharMerica from a “hold” rating to a “buy” rating in a research report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. PharMerica has a consensus rating of “Hold” and an average price target of $30.50.

A number of institutional investors have recently modified their holdings of the business. California Public Employees Retirement System increased its position in PharMerica by 5.6% during the 3rd quarter. California Public Employees Retirement System now owns 97,587 shares of the company’s stock valued at $2,859,000 after purchasing an additional 5,187 shares during the period. Allianz Asset Management GmbH grew its position in shares of PharMerica by 3,347.4% in the 3rd quarter. Allianz Asset Management GmbH now owns 399,591 shares of the company’s stock worth $11,708,000 after buying an additional 388,000 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of PharMerica by 1.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 269,518 shares of the company’s stock worth $7,897,000 after buying an additional 3,864 shares during the period. WINTON GROUP Ltd purchased a new stake in shares of PharMerica in the 3rd quarter worth about $2,150,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of PharMerica in the 3rd quarter worth about $7,031,000. 89.97% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “PharMerica Co. (PMC) CEO Sells $15,241,853.25 in Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/11/pharmerica-co-pmc-ceo-sells-15241853-25-in-stock.html.

About PharMerica

Insider Buying and Selling by Quarter for PharMerica (NYSE:PMC)

Receive News & Ratings for PharMerica Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Co. and related companies with MarketBeat.com's FREE daily email newsletter.